Katie Cooke

Mrs. Katie Cooke


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
MCMatthew Cronin
Matthew Cronin
RKRuth Kieran
Ruth Kieran
CSClara Steele
Clara Steele
KCKatie Cooke
Katie Cooke
SOSeamus O'Reilly
Seamus O'Reilly
Background: Oncology medication costs are increasing internationally; patient attitudes towards these costs remain unclear. Methods: A three-part cross-sectional questionnaire was distributed to patients with breast cancer to determine their attitudes towards oncology medication costs and to explore potential patient-acceptable methods to reduce these costs. Results: A total of 321 patients were eligible for inclusion and 180 fully completed the questionnaire (56.1% response rate). Overall, 67.8% (N = 122/180) of patients found the costs presented in the questionnaire to be unacceptable. 92.2% (N = 166/180), 87.8% (N = 158/180) and 68.9% (N = 124/180) of participants found the costs of pembrolizumab, palbociclib and trastuzumab respectively to be unacceptable. A total of 72.8% (N = 131/180) of patients indicated that they would like to be better informed about the societal costs of their cancer treatment and 81.1% (N = 146/180) of patients believed that reducing the costs of cancer treatment to society is important. There was a statistically significant difference in patient desires to be better informed of societal drug costs between those with early-stage breast cancer and those with metastatic disease (75.8% vs. 47.4%, χ2 = 6.923, p = 0.009). Conclusions: These findings indicate that many Irish patients with breast cancer find the societal costs of oncology medications to be unacceptable, and many patients have a desire to be better informed of these costs.

6 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MCMatthew Cronin
Matthew Cronin
RKRuth Kieran
Ruth Kieran
CSClara Steele
Clara Steele
KCKatie Cooke
Katie Cooke
SOSeamus O'Reilly
Seamus O'Reilly
Background: Oncology medication costs are increasing internationally; patient attitudes towards these costs remain unclear. Methods: A three-part cross-sectional questionnaire was distributed to patients with breast cancer to determine their attitudes towards oncology medication costs and to ex-plore potential patient acceptable methods to reduce these costs. Results: 321 patients were eligible for inclusion and 180 fully completed the questionnaire (56.1% response rate). Overall, 67.8% (N = 122/180) of patients found the costs presented in the questionnaire to be unacceptable. 92.2% (N = 166/180), 87.8% (N = 158/180) and 68.9% (N = 124/180) of participants found the costs of pembrolizumab, palbociclib and trastuzumab respectively to be unacceptable. 72.8% (N = 131/180) of patients indicated that they would like to be better informed about the societal costs of their cancer treatment and 81.1% (N = 146/180) of patients believed that reducing the costs of cancer treatment to society is important. There was a statistically significant difference in patient desires to be better informed of societal drug costs between those with early-stage breast cancer and those with metastatic disease (75.8% vs 47.4%, χ2 = 6.923, p = 0.009). Conclusion: These findings indicate that many Irish patients with breast cancer find the societal costs of oncology medications to be unacceptable, and many patients have a de-sire to be better informed of these costs.